MNPR
Monopar TherapeuticsCompany Information
- Company Name
- Monopar Therapeutics
- CIK
- CIK0001645469
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MNPR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MNPR
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-26
- Last sale
- 2026-09-24
- Shares purchased (TTM)
- 1,500
- Shares sold (TTM)
- 591,639
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 6,224,910
- Shares outstanding
- 8,542,450
- Ownership
- 72.87%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 2.32%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 53 | 53 | 62 | 128 | 40 | 40 | 46 | 6 | 6 | 8 | 7 | 6 | ||||||
| Investments | 82 | 85 | 79 | 16 | 14 | 15 | 14 | - | 1 | 1 | 0 | 3 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 135 | 138 | 140 | 144 | 54 | 55 | 60 | 6 | 7 | 9 | 7 | 9 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 135 | 138 | 141 | 144 | 54 | 55 | 60 | 6 | 7 | 9 | 7 | 9 | ||||||
| Accounts Payable And Accrued Liabilities Current | 4 | 2 | 3 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 4 | 2 | 3 | 3 | 2 | - | 5 | - | - | - | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Liabilities | 4 | 3 | 3 | 3 | 2 | 1 | 5 | 1 | 1 | 1 | 2 | 2 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 229 | 229 | 227 | 226 | 133 | 132 | 131 | 70 | 70 | 69 | 66 | 65 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -99 | -93 | -90 | -84 | -81 | -78 | -76 | -65 | -64 | -62 | -60 | -58 | ||||||
| Stockholders Equity | 131 | 135 | 138 | 142 | 52 | 54 | 55 | 5 | 6 | 7 | 6 | 7 | ||||||
| Liabilities And Stockholders Equity | 135 | 138 | 141 | 144 | 54 | 55 | 60 | 6 | 7 | 9 | 7 | 9 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | ||||||
| Common Stock Shares Issued | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 4 | 4 | 3 | 3 | 3 | ||||||
| Shares Outstanding | 7 | 7 | 7 | 7 | 6 | 6 | 6 | 4 | 4 | 3 | 3 | 3 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMonopar Therapeutics (MNPR) — SEC Financial Statements & Analysis
Monopar Therapeutics (MNPR) is a pharmaceutical preparations company, incorporated in DE. Monopar Therapeutics trades on Nasdaq as: MNPR. Monopar Therapeutics (MNPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Monopar Therapeutics carries a market cap of $790.95M, a P/E ratio of -44.32x, a P/B ratio of 6.04x, an enterprise value of $738.19M, and an EV/EBITDA multiple of -33.37x. On profitability, it posts a Return on Equity (ROE) of -19.50%, a Return on Assets (ROA) of -18.90%, and a Return on Invested Capital (ROIC) of -48.72%. Per share, it reports EPS of $-2.09, free cash flow per share of $-1.43, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 3.10% year-over-year and EPS growth of -15.54% year-over-year. On the balance sheet, it maintains a current ratio of 33.56x, a quick ratio of 33.56x, working capital of $130.75M, a debt-to-equity ratio of 0.03x, a debt ratio of 0.03, an interest coverage ratio of -240.36x, free cash flow of $-12.18M (TTM), and net debt of $-52.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $790.95M
- P/E TTM
- -44.32x
- EPS TTM
- $-2.09
- P/B TTM
- 6.04x
- ROE TTM
- -19.50%
- ROA TTM
- -18.90%
- Debt To Equity
- 0.03x
- Free Cash Flow TTM
- $-12.18M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Monopar Therapeutics in?
Monopar Therapeutics (MNPR) operates in the Pharmaceutical Preparations industry.
What exchange does MNPR trade on?
Monopar Therapeutics (MNPR) trades on the Nasdaq.
Where is Monopar Therapeutics incorporated?
Monopar Therapeutics is incorporated in DE.
When was Monopar Therapeutics (MNPR)'s most recent SEC filing?
Monopar Therapeutics (MNPR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is MNPR's market cap?
Monopar Therapeutics (MNPR) has a market capitalization of $790.95M as of 2026-06-30.
What is MNPR's EPS (earnings per share)?
Monopar Therapeutics (MNPR)'s trailing twelve month EPS is $-2.09 as of 2026-06-30.
What is MNPR's ROE (return on equity)?
Monopar Therapeutics (MNPR)'s trailing twelve month Return on Equity (ROE) is -19.50% as of 2026-06-30.
What is MNPR's ROA (return on assets)?
Monopar Therapeutics (MNPR)'s trailing twelve month Return on Assets (ROA) is -18.90% as of 2026-06-30.
What is MNPR's ROIC (return on invested capital)?
Monopar Therapeutics (MNPR)'s trailing twelve month Return on Invested Capital (ROIC) is -48.72% as of 2026-06-30.
What is MNPR's EV/EBITDA?
Monopar Therapeutics (MNPR)'s trailing twelve month EV/EBITDA is -33.37x as of 2026-06-30.